Cannabis Law Report

AUGUST 7, 2021

We are currently focused on developing MDMA-assisted therapy as a Breakthrough Therapy for PTSD, with plans to submit for FDA approval in 2023. The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times. Key Responsibilities.

Clinical Trials 105

Clinical Trials Research and Development Compliance Compliance 105

Veriheal

JULY 18, 2023

This could foster a pool of experts well-versed in applying psychedelic-assisted therapy. Clinical Trials and Reporting The bill breaks new ground by allowing clinical trials to take place regardless of whether the tested substances fall under federal or military statutes.

Treatment 98

Treatment Clinical Trials Research and Development Legislation 98

MMJ Recs

JULY 30, 2024

While conventional therapies such as psychotherapy and medications are widely used, they do not uniformly alleviate symptoms for all individuals. Conventional treatments for PTSD primarily include psychotherapy, such as cognitive behavioral therapy, and medications like antidepressants and anti-anxiety drugs.

Therapy 116

Therapy Treatment Clinical Trials Sleep 116

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. This is the largest trial ever conducted in psilocybin therapy, and it was done amid the lockdowns and challenges of the COVID pandemic. million, or $0.79

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

JULY 24, 2021

“The groundbreaking progress that we’ve seen from the Multidisciplinary Association for Psychedelic Studies (MAPS) in its Phase 3 clinical trials of MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD), including receiving Breakthrough Therapy Designation from the Food and Drug Administration (FDA), shows great promise to date.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

CannaMD

JUNE 2, 2021

Of those states that had legalized medical marijuana, 14 currently consider Parkinson’s disease a qualifying condition for medical marijuana therapies. Of those who were provided information, the most common sources were non-Parkinson’s disease doctors, dispensary staff, and other individuals with Parkinson’s.

Patients 105

Patients Clinical Trials Treatment Research and Development 105

Cannabis Law Report

JULY 28, 2021

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study.

Clinical Trials 81

Clinical Trials Research and Development Treatment Therapy 81

Veriheal

JUNE 30, 2023

For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Veriheal

AUGUST 28, 2023

New therapy exploration suggest potential in using psilocybin for OCD symptoms. And it further reinforces the need to carry out clinical trials to determine the safety and efficiency of using psilocybin to treat OCD. Preliminary findings have suggested that mental health patients could go through psilocybin-assisted therapy.

Treatment 78

Treatment Clinical Trials Therapy Research and Development 78

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.

Clinical Trials 8

Clinical Trials Pharmaceutical Cannabinoids Data 8

Puff Puff Post

MARCH 10, 2020

INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. For more information, visit www.inmedpharma.com. About INM-755: INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

OCTOBER 22, 2021

(TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a neuropharmaceutical company focused on psychedelic-assisted therapies, is pleased to announce that following discussions with the U.K. Small Pharma initiated a clinical program into DMT-assisted therapy in February 2021. For further information contact: .

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

Cannabis Law Report

AUGUST 18, 2022

The firm’s deep expertise in pharmaceutical sciences, FDA regulatory compliance and pharmaceutical product liability litigation and risk management enables it to address complex legal hurdles faced by stakeholders seeking to research, develop, invest in and bring-to-market psychedelic therapies. BUFFALO, N.Y. , Aug. Tweet this.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

MMJ Recs

JULY 9, 2024

Disease-modifying therapies (DMTs) are essential in altering the immune response to reduce inflammation and prevent further damage to the nervous system. Additionally, no current treatments can reverse existing neurological damage, highlighting the need for ongoing research into more effective therapies and potential cures.

Marijuana 111

Marijuana Treatment Cannabinoids Patients 111

Cannabis Law Report

JUNE 4, 2021

Additionally, this novel antibody conjugate demonstrated very good tolerability during this DLT phase 1 trial. Clinical trial information: NCT03276572 ( [link] ). Our diverse pipeline of therapeutics includes therapies for pancreatic cancer and prostate cancer. Abstract Number: 5015. About AIkido Pharma Inc.

Data 100

Data Research and Development Clinical Trials Therapy 100

The Cannigma

FEBRUARY 2, 2021

We also lack information about the extent to which the PD community is informed about medicinal cannabis and whether they have tried cannabis and, if so, with what result.”. million clinical trial investigating the effects of CBD on hallucinations and delusions related to the disease. Still, research is ongoing.

Patients 107

Patients Clinical Trials Research and Development Treatment 107

Cannabis Law Report

SEPTEMBER 9, 2021

MYMD-1 is also being developed as a potential therapy for COVID-19-related conditions such as post-COVID-19 syndromes. Supera-CBD is being developed to address anxiety, chronic pain, addiction, and seizures, and is on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain. 646) 421-9523.

Pharmaceutical 74

Pharmaceutical Clinical Trials Chronic Pain Epilepsy 74

Cannabis Law Report

DECEMBER 2, 2021

(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.

Clinical Trials 40

Clinical Trials Data Patients THC 40

Cannabis Law Report

AUGUST 25, 2021

Lucid has successfully developed a strong pipeline of novel therapeutic compounds — supported by IP in order to advance to future clinical trials — and we are confident that the experience the Lucid leadership team brings will allow us to immediately start the process towards clinical trials to further advance these promising therapies.

Clinical Trials 85

Clinical Trials Research and Development Therapy Conditions 85

Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. For more information, visit www.mymd.com. in the blood.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Therapy 40

The Joint Blog

NOVEMBER 4, 2019

Researchers were from the Mayo Clinic. The study found that 58% of physicians agree that “medical cannabis was a legitimate medical therapy.” ” The study concludes: “Providers generally believe that medical cannabis is a legitimate medical therapy. A majority (>?50%) Conclusions.

Therapy 42

Therapy Clinical Trials Conditions Patients 42

Cannabis Law Report

JULY 9, 2021

The use of psychedelic substances to treat mental illness and physical disorders is known as “psychedelic therapy.” In a typical scenario, psychedelic substances would be used in conjunction with psychotherapy sessions to treat disorders for which other medicinal therapies have failed. Psychedelic therapy is not a fringe phenomenon.

Law 81

Law Therapy Clinical Trials Research and Development 81

Cannabis Law Report

DECEMBER 5, 2021

Revenue share payments will be based on North America sales of MDMA for use in MDMA-assisted therapy, will terminate after 8 years, and include a reciprocity payment structure that reduces payments once certain financial milestones are met. Interested prospective funders can submit their contact information here.

Therapy 52

Therapy Access Research and Development Clinical Trials 52

MMJ Recs

JULY 11, 2024

Each type of insomnia may require different treatment approaches, including behavioral therapy, medication, lifestyle changes, or addressing underlying medical or psychological issues. For more information about the products and strains that work best for insomnia, read our A Guide to the Most Popular MMJ Strains.

Sleep 111

Sleep Treatment Research and Development Therapy 111

Canna Care Docs

OCTOBER 3, 2023

As a devastating diagnosis, patients with a terminal illness must not only learn to cope with this information about their health but find restorative ways to alleviate the most common symptoms and effects. One study from the Journal of Clinical Oncology examined the efficacy of cannabinoids in appetite stimulation.

Chronic Pain 105

Chronic Pain Clinical Trials Patients Cannabinoids 105

Veriheal

MAY 26, 2022

Dedicated to “redefining what’s possible,” the 501(c)(3) organization has provided 1:1 support and resources to over 69,000 clients as they navigated plant-powered cannabinoid therapy. The ORR, an ongoing online survey study, collects self-reported health information to be analyzed by Johns Hopkins for published research papers.

Advocacy 98

Advocacy Patients Clinical Trials Education 98

TheAnswerPage

JANUARY 11, 2022

In fact, from pediatricians to geriatricians, I cannot think of any medical practitioner that does not need to be well informed about the endocannabinoid system and cannabis-based therapeutics. Who monitors their health and the long-term effects of the marijuana therapy?

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

NOVEMBER 23, 2021

Crystalline psilocybin is used in COMP360, COMPASS’s synthesised psilocybin formulation being developed for psilocybin therapy in TRD. Patents enable us to continue to do the highest quality clinical research so we can work to bring therapies to patients who are suffering with serious mental health challenges and have few options.”

Clinical Trials 52

Clinical Trials Therapy Research and Development Media 52

Cannabis Law Report

JULY 28, 2021

We look forward to providing continued updates on our intellectual property, research, clinical, regulatory and manufacturing activities for PD-001; our novel oral formulation of cepharanthine, with the aim of working towards a first-in-human, proof-of-concept clinical trial under an FDA IND approval.” ” Next Steps.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

JULY 27, 2021

Research opportunities such as the ORR expand the existing scientific knowledge base to better inform clinical decision making, and also dispels the stigma surrounding medicinal cannabis use.”. plan to conduct a controlled clinical trial to further understand the effects of CBD in epilepsy treatment.

Data 81

Data Epilepsy Research and Development Clinical Trials 81

Veriheal

APRIL 11, 2022

I look forward to a time when they are not considered alternative therapies or home remedies but actually first-line therapies,” said the CEO of Zelira, Oludare Odumosu. “We Additionally, numerous other cannabis-based medications have already gained approval or are in the process of being tested in clinical trials.

Pharmaceutical 105

Pharmaceutical Research and Development DEA Clinical Trials 105

Miss Marijuana

FEBRUARY 7, 2025

It’s important to stay informed about current laws because they affect everything from what products are available to how they can be used. Keep up to date with reliable sources, like NORML , to stay informed about the latest developments. When we talk about federal vs. state regulations , it gets interesting.

THC 52

THC CBD Chronic Pain Cannabinoids 52

The Cannigma

AUGUST 31, 2021

Barely a quarter of cannabis users trust their doctor to provide them with reliable information about medical cannabis and how to use it to treat their medical or health conditions, according to a recent survey. People want to trust their doctors, but doctors need knowledge.

Education 105

Education Clinical Trials Medicine Policy 105

SpeedWeed

SEPTEMBER 17, 2021

million to assess the efficacy of Multidisciplinary Association for Psychedelic Studies (MAPS) MDMA-assisted therapy to treat traumatic brain injury (TBI). Wesana is a serious, thoughtful and ethical company engaged in the development of psychedelic-assisted therapy. Lately, MAPS research zeroed in on MDMA-assisted therapy for PTSD.

Clinical Trials 53

Clinical Trials Research and Development Therapy Treatment 53

Peninsula Alternative Health

MAY 15, 2019

With clinical research developing rapidly in Israel and with the use of innovative technology we hope to have this information in the near future. Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy.

Conditions 40

Conditions Therapy Cannabinoids Epilepsy 40

Cannabis Law Report

AUGUST 3, 2021

Visit adnas.com for more information. FDA) or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. Applied DNA is also the manufacturer of the EUA-authorized Linea™ COVID-19 Assay Kit. Follow us on Twitter and LinkedIn.

Clinical Trials 81

Clinical Trials Therapy Collective Research and Development 81